Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dose Dense Gemcitabine and Cisplatin in MIBC
NCT01611662Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- May 2012
- Primary completion
- Jul 2013
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, Cisplatin micelle injection (HA132) in Muscle Invasive Bladder Cancer (MIBC), sponsored by Fox Chase Cancer Center. Started May 2012; status: terminated.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT01611662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01611662.